



Ref: Syn/CS/SE/PR/2022-23/Oct/06

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

October 19, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release in respect of results for the quarter ended September 30, 2022.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled **“Syngene reports second quarter results Revenue from operations up 26% to Rs. 768 crores, PAT increased 11% to Rs. 102 crores”**

The above-mentioned press release will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed: Press Release along with fact sheet

Press Release

Syngene reports second quarter results
Revenue from operations up 26% to Rs. 768 crores,
PAT increased 11% to Rs. 102 crores

Bangalore, October 19, 2022: Syngene International Limited today announced its second quarter and first half results. The Company reported quarterly revenue from operations growth of 26% year-on-year to Rs. 768 crores; profit after tax for the quarter, before an exceptional item, increased by 11% year-on-year to Rs. 102 crores.

Commenting on the results, **Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited**, said, *"The quarter saw positive performances across all divisions. Our research divisions: Discovery Services, including Synvent, our integrated drug discovery platform, and the Dedicated Centres showed sustained growth. Discovery Chemistry in particular saw buoyant customer demand.*

Growth in Development Services was led by existing clients renewing contracts and setting up collaborations on additional projects. The highlight in Manufacturing Services was the successful completion of the process performance qualification batches at a commercial scale for Zoetis. We are on track for the next important regulatory audits which will pave the way for the commercial manufacturing of the drug substance for Librela[®], a Zoetis product, from the fourth quarter of FY23.*

With a strong first half of the year behind us we are on track to achieve our guidance, including the upgraded revenue growth target announced in July."

Sibaji Biswas, Chief Financial Officer, Syngene International Limited added.

"Forward planning with suppliers prevented supply chain disruption and, despite the rising global inflation, cost discipline helped us maintain EBITDA margins at similar levels as last year.

Overall, we are seeing healthy signs of growth in the market for contract research, development and manufacturing services and we continue to invest in infrastructure and capability development to meet these opportunities.”

Quarterly Financial Highlights (All numbers are in Indian rupees in Crores except margins)

	Q2 FY23	Q2 FY22	YoY Change (%)
Revenue from Operations	768	610	26
Revenue	784	623	26
Reported EBITDA	232	190	22
EBITDA margin (%)	29.6%	30.5%	
PAT before exceptional item	102	92	11
PAT Margin (%)	13.0%	14.8%	
PAT after exceptional item (Note1)	102	67	53

H1 FY22 Financial Highlights (All numbers are in Indian rupees in Crores except margins)

	H1 FY23	H1 FY22	YoY Change (%)
Revenue from operations	1,413	1,205	17
Revenue	1,444	1,230	17
Reported EBITDA	420	368	14
EBITDA Margin (%)	29.1%	29.9%	
PAT before exceptional item	176	169	4
PAT Margin (%)	12.2%	13.8%	
PAT after exceptional item (Note 1)	176	144	22

Note 1: Exceptional item relating to Q2FY22 pertains to an exceptional downward adjustment of Rs. 25 crores (net of tax) on account of the Government’s decision during that quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 5 crores for the Financial Year 2020.

Business updates

The second quarter results reflect positive performances across all divisions. Discovery Services experienced sustained demand and Development Services benefitted from repeat orders by existing clients, especially in areas of drug substance development and clinical supplies.

In Manufacturing Services, as part of the long-term biologics manufacturing agreement signed with Zoetis in the first quarter, the Company completed the process performance qualification batches at a commercial scale. The commercial manufacturing of the drug substance for Librela®* is likely to begin in the fourth quarter of FY23, subject to successful completion of the required audits.

Underlying performance for the first half, excluding the impact of remdesivir in the previous year, was strong and reflects a return to normal operations in global markets. After a decade of partnering with Zoetis, the Company signed a long-term biologics manufacturing agreement in July 2022 which adds to Syngene's well-established research partnerships with BMS and Amgen. The agreement will leverage recent investments in biologics infrastructure and is expected to be transformational for the Manufacturing Services division in the years to come. The agreement has the potential to be worth up to \$500 million over the next 10 years.

**Librela® is a first-of-its-kind injectable monoclonal antibody used for the alleviation of pain associated with osteoarthritis in dogs.*

Earnings call

Syngene will host an investor call at 12 noon IST on October 20, 2022, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279/ +91 22 7115 8180. Other toll numbers are listed in the conference call invitation which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available until October 27, 2022 on +91 22 71945757/ +91 22 66635757,

Playback ID: **93954**. We will aim to post the transcript of the conference call on the Company website within seven working days of the investor conference call.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 5200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com

Contact details

Investor Contact	Media Contact
Krishnan G P: +91 80 6891 9807 M: +919819992927 Fax: +91 80 2852 3423 E: krishnan.g@syngeneintl.com	Shotorupa Ghosh M: +91 8450977080 Fax: +91 80 2852 3423 E: Shotorupa.ghosh@syngeneintl.com

Disclaimer: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.*

SYNGENE GROUP

FACT SHEET

**Unaudited financial results for the quarter ended 30 September 2022
(Consolidated)**



SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)		(Rs. Millions)	
BALANCE SHEET		30 September 2022	31 March 2022
ASSETS			
Non-current assets			
Property, plant and equipment	22,621	21,229	
Capital work-in-progress	2,291	3,464	
Right-of-use assets	2,202	2,188	
Investment property	516	385	
Other intangible assets	115	126	
Financial assets			
(i) Investments	1,303	2,703	
(ii) Derivative assets	938	1,249	
(iii) Other financial assets	915	203	
Deferred tax assets (net)	1,039	656	
Income tax assets (net)	1,651	1,191	
Other non-current assets	198	185	
Total non-current assets	33,789	33,579	
Current assets			
Inventories	2,667	1,794	
Financial assets			
(i) Investments	8,292	7,638	
(ii) Trade receivables	4,396	5,077	
(iii) Cash and cash equivalents	1,592	2,618	
(iv) Bank balances other than (iii) above	1,159	2,561	
(v) Derivative assets	403	842	
(vi) Other financial assets	514	384	
Other current assets	999	1,145	
Total current assets	20,022	22,059	
Total assets	53,811	55,638	
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4,014	4,008	
Other equity	28,725	28,968	
Total equity	32,739	32,976	
LIABILITIES			
Non-current liabilities			
Financial liabilities			
(i) Borrowings	5,488	5,315	
(i)(a) Lease liabilities	2,152	2,102	
(ii) Derivative liabilities	507	84	
Provisions	416	344	
Other non-current liabilities	2,158	2,528	
Total non-current liabilities	10,721	10,373	
Current liabilities			
Financial liabilities			
(i) Borrowings	2,209	2,581	
(i)(a) Lease liabilities	241	218	
(ii) Trade payables	2,429	2,328	
(iii) Derivative liabilities	553	8	
(iv) Other financial liabilities	847	1,098	
Provisions	678	582	
Current tax liabilities (net)	528	240	
Other current liabilities	2,866	5,234	
Total current liabilities	10,351	12,289	
Total equity and liabilities	53,811	55,638	

(Rs. Millions)

KEY FINANCIAL INFORMATION

		F22	F23	Movement
		Q2	Q2	%
Revenue from operations	<i>Rs. Mn</i>	6,102	7,681	25.9
EBITDA from operations	<i>Rs. Mn</i>	1,774	2,165	22.0
EBITDA from operations margin	%*	29.1	28.2	-89bps
PAT before exceptional item	<i>Rs. Mn</i>	920	1,020	10.9
PAT margin	%	14.8	13.0	-175bps

		F22	F23	Movement
		Q2	Q2	%
Revenue from operations	<i>Rs. Mn</i>	6,102	7,681	25.9
Other income	<i>Rs. Mn</i>	129	154	19.7
Reported revenue	<i>Rs. Mn</i>	6,231	7,835	25.7
Material costs	<i>Rs. Mn</i>	(1,675)	(1,990)	18.8
	%*	(27.4)	(25.9)	154bps
Staff costs	<i>Rs. Mn</i>	(1,892)	(2,185)	15.5
	%*	(31.0)	(28.4)	255bps
Other direct costs#	<i>Rs. Mn</i>	(207)	(288)	38.9
	%*	(3.4)	(3.7)	-35bps
Other expenses	<i>Rs. Mn</i>	(659)	(868)	31.7
	%*	(10.8)	(11.3)	-50bps
Foreign exchange fluctuation (gain)/loss, net	<i>Rs. Mn</i>	104	(186)	(279.1)
EBITDA	<i>Rs. Mn</i>	1,903	2,319	21.8
Depreciation and amortisation expenses	<i>Rs. Mn</i>	(762)	(902)	18.4
EBIT	<i>Rs. Mn</i>	1,141	1,417	24.1
Finance costs	<i>Rs. Mn</i>	(12)	(117)	866.9
PBT	<i>Rs. Mn</i>	1,129	1,300	15.1
Tax	<i>Rs. Mn</i>	(209)	(280)	34.2
PAT before exceptional item	<i>Rs. Mn</i>	920	1,020	10.9
Exceptional item (refer note)	<i>Rs. Mn</i>	(253)	-	n/a
PAT after exceptional item	<i>Rs. Mn</i>	667	1,020	52.9

includes power, utility and clinical trial cost

* % over revenue from operations

Note: Exceptional item relating to Q2FY22 pertains to an exceptional downward adjustment of Rs. 253 million (net of tax) on account of the Government's decision during that quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 50 million for the Financial Year 2020.

(Rs. Millions)

KEY FINANCIAL INFORMATION

		F22 H1	F23 H1	Movement %
Revenue from operations	<i>Rs. Mn</i>	12,047	14,126	17.3
EBITDA from operations	<i>Rs. Mn</i>	3,424	3,892	13.7
EBITDA from operations margin	%*	28.4	27.6	-87bps
PAT before exceptional item	<i>Rs. Mn</i>	1,693	1,759	3.9
PAT margin	%	13.8	12.2	-158bps

		F22 H1	F23 H1	Movement %
Revenue from operations	<i>Rs. Mn</i>	12,047	14,126	17.3
Other income	<i>Rs. Mn</i>	252	309	22.8
Reported revenue	<i>Rs. Mn</i>	12,299	14,435	17.4
Material costs	<i>Rs. Mn</i>	(3,621)	(3,602)	(0.5)
	%*	(30.1)	(25.5)	456bps
Staff costs	<i>Rs. Mn</i>	(3,656)	(4,156)	13.7
	%*	(30.3)	(29.4)	92bps
Other direct costs#	<i>Rs. Mn</i>	(387)	(571)	47.6
	%*	(3.2)	(4.0)	-83bps
Other expenses	<i>Rs. Mn</i>	(1,217)	(1,684)	38.4
	%*	(10.1)	(11.9)	-182bps
Foreign exchange fluctuation (gain)/loss, net	<i>Rs. Mn</i>	258	(220)	(185.2)
EBITDA	<i>Rs. Mn</i>	3,676	4,202	14.3
Depreciation and amortisation expenses	<i>Rs. Mn</i>	(1,509)	(1,763)	16.8
EBIT	<i>Rs. Mn</i>	2,167	2,439	12.6
Finance costs	<i>Rs. Mn</i>	(91)	(211)	132.2
PBT	<i>Rs. Mn</i>	2,076	2,228	7.3
Tax	<i>Rs. Mn</i>	(383)	(469)	22.4
PAT before exceptional item	<i>Rs. Mn</i>	1,693	1,759	3.9
Exceptional item (refer note)	<i>Rs. Mn</i>	(253)	-	n/a
PAT after exceptional item	<i>Rs. Mn</i>	1,440	1,759	22.1

includes power, utility and clinical trial cost

* % over revenue from operations

Note: Exceptional item relating to Q2FY22 pertains to an exceptional downward adjustment of Rs. 253 million (net of tax) on account of the Government's decision during that quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 50 million for the Financial Year 2020.

KEY FINANCIAL INFORMATION

		F22	F22	F22	F22	F23	F23
		Q1	Q2	Q3	Q4	Q1	Q2
Revenue from operations	<i>Rs. Mn</i>	5,945	6,102	6,413	7,582	6,445	7,681
EBITDA from operations	<i>Rs. Mn</i>	1,650	1,774	2,034	2,504	1,728	2,165
EBITDA from operations margin	<i>%*</i>	27.8	29.1	31.7	33.0	26.8	28.2
PAT before exceptional item	<i>Rs. Mn</i>	773	920	1,040	1,477	739	1,020
PAT margin	<i>%</i>	12.7	14.8	15.9	19.1	11.2	13.0

		F22	F22	F22	F22	F23	F23
		Q1	Q2	Q3	Q4	Q1	Q2
Revenue from operations	<i>Rs. Mn</i>	5,945	6,102	6,413	7,582	6,445	7,681
Other income	<i>Rs. Mn</i>	123	129	130	147	155	154
Reported revenue	<i>Rs. Mn</i>	6,068	6,231	6,543	7,728	6,600	7,835
Material costs	<i>Rs. Mn</i>	(1,946)	(1,675)	(1,721)	(2,149)	(1,612)	(1,990)
	<i>%*</i>	(32.7)	(27.4)	(26.8)	(28.3)	(25.0)	(25.9)
Staff costs	<i>Rs. Mn</i>	(1,765)	(1,892)	(1,954)	(1,797)	(1,971)	(2,185)
	<i>%*</i>	(29.7)	(31.0)	(30.5)	(23.7)	(30.6)	(28.4)
Other direct costs#	<i>Rs. Mn</i>	(180)	(207)	(246)	(238)	(283)	(288)
	<i>%*</i>	(3.0)	(3.4)	(3.8)	(3.1)	(4.4)	(3.7)
Other expenses	<i>Rs. Mn</i>	(558)	(659)	(656)	(986)	(817)	(868)
	<i>%*</i>	(9.4)	(10.8)	(10.2)	(13.0)	(12.7)	(11.3)
Foreign exchange fluctuation (gain)/loss, net	<i>Rs. Mn</i>	154	104	198	91	(34)	(186)
EBITDA	<i>Rs. Mn</i>	1,773	1,903	2,164	2,651	1,883	2,319
Depreciation and amortisation expenses	<i>Rs. Mn</i>	(747)	(762)	(785)	(803)	(861)	(902)
EBIT	<i>Rs. Mn</i>	1,026	1,141	1,379	1,848	1,021	1,417
Finance costs	<i>Rs. Mn</i>	(79)	(12)	(95)	(56)	(94)	(117)
PBT	<i>Rs. Mn</i>	947	1,129	1,284	1,792	928	1,300
Tax	<i>Rs. Mn</i>	(174)	(209)	(244)	(314)	(189)	(280)
PAT before exceptional item	<i>Rs. Mn</i>	773	920	1,040	1,477	739	1,020
Exceptional item (refer note)	<i>Rs. Mn</i>	-	(253)	-	-	-	-
PAT after exceptional item	<i>Rs. Mn</i>	773	667	1,040	1,477	739	1,020

includes power, utility and clinical trial cost

* % over revenue from operations

Note: Exceptional item relating to Q2FY22 pertains to an exceptional downward adjustment of Rs. 253 million (net of tax) on account of the Government's decision during that quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 50 million for the Financial Year 2020.